Advisory Committee on the Medical Uses of Isotopes Update to the Organization of Agreement States August 29, 2012. Darice Bailey Texas Department of State Health Services ACMUI Agreement State Representative. ACMUI Purpose. Represents radioactive material users in the medical community.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Advisory Committee on the Medical Uses of Isotopes Update to the Organization of Agreement StatesAugust 29, 2012
Texas Department of State Health Services
ACMUI Agreement State Representative
Represents radioactive material users in the medical community.
Provides a public forum to bring key issues and technical perspectives to the NRC’s attention.
Provides technical and clinical expertise to NRC on medical uses of radioactive materials.
Recommends and comments on changes to NRC regulations and guidance, as well as changes in procedures.
Provides professional evaluation to NRC for
“It truly is daunting”-Spring Awakening
Chairman: Leon S. Malmud, M.D., Health Care Administrator
Vice Chairman: Bruce R. Thomadsen, Ph.D., Medical Physicist, Radiation Therapy
Members:Darice G. Bailey, Agreement State RepresentativeMilton J. Guiberteau, M.D., Diagnostic RadiologistSusan M. Langhorst, Ph.D., Radiation Safety OfficerSteven R. Mattmuller, Nuclear PharmacistChristopher J. Palestro, M.D., Nuclear Medicine PhysicianJohn H. Suh, M.D., Radiation Oncologist Orhan H. Suleiman, Ph.D., FDA RepresentativeWilliam A. Van Decker, M.D., Nuclear CardiologistLaura M. Weil, Patients' Rights AdvocateJames S. Welsh, M.D., Radiation OncologistPat B. Zanzonico, Ph.D., Medical Physicist, Nuclear Medicine
Steps required for appointment.
Public meeting, fully transcribed – differs from working group meetings, etc.
Extremely kind treatment.
ACMUI represents radioactive material users in the medical community.
Through interaction with ACMUI, States have access to concerns and issues from a larger pool of licensees.
ACMUI provides a public forum to bring key issues and technical perspectives to the NRC’s attention.
Through interaction with ACMUI, the Agreement States have an additional forum to use for bringing information to NRC, as well as receiving information from medical licensees.
ACMUI provides technical and clinical expertise to NRC on medical uses of radioactive materials.
Through interaction with ACMUI the Agreement States have access to a wealth of knowledge and expertise.
State issues and positions should be brought to ACMUI through the ACMUI Agreement State representative.
Participate in NRC/OAS/CRCPD conference calls.
Review NMED and ask questions of states regarding medical events.
Provide agenda information to the OAS Board and bring issues/positions to ACMUI meetings.
Provide post-meeting information to the Board
Offer agenda items for ACMUI as provided by OAS.
Review agenda items.
Seek information from membership.
Provide information to ACMUI representative.
Contact representative with medical use issues/positions/concerns as they arise.
Keep representative informed on state efforts regarding medical use/issues.
Let the exchange begin!
Medical Event Definition
ACMUI’s position was finalized prior to this meeting. NRC staff presented what they were proposing to the Commission. You received the most up to date information this morning.
Medical Events Subcommittee Report
Subcommittee reviews NMED and presents an annual review of medical events to the full ACMUI.
Agreement State (AS) entries are included. A question arose regarding one AS entry.
Electronic Signatures Subcommittee Report
ACMUI approved the subcommittee’s report which provided guidance to NRC staff to accept electronic signatures as defined in the guidance of the E-Sign Act (Public Law No. 106-229).
The term ‘‘electronic signature’’ means an electronic sound, symbol, or process, attached to or logically associated with a contract or other record and executed or adopted by a person with the intent to sign the record.
Medical Use of Radium-223 Dichloride
A representative from the manufacturer provided an overview of the clinical and radiation safety aspects of the medical use of Radium-223 dichloride.
ACMUI member, Dr. Zanzonico, discussed the regulatory aspects of the medical use of Radium-223 dichloride.
Medical Use of Radium-223 dichloride
A subcommittee was created to provide a recommendation on licensing for alpha-emitters, including Radium-223.
The subcommittee presented its report to the full ACMUI on July 9 via a publicly noticed conference call. The report was approved with modifications.
NRC staff provided an update on the strontium breakthrough with rubidium-82 generators from an NRC perspective.
ACMUI member, Dr. Suleiman, presented an update from the FDA perspective.
A desire to hear lessons learned from Florida and Nevada was voiced by the committee.
NRC staff provided information regarding intentions to prepare a large Part 35 rule change for comment within the year.
It is anticipated that the Medical Events definition will be included in that proposal.
Large package is result of being responsive to the states and the impacts of cumulative effects of regulation.
Reducing Occupational Dose Limits
Domestic production of Molybdenum-99
Part 35 Updates from NRC staff
Patient Release Data Collection update
Proposed Regulatory Changes for Permanent Implant Brachytherapy Programs update
Use of Dose Calibrators in Medicine
ACMUI Reporting Structure
Do any states have unique patient release criteria, inspection techniques, etc?
Are there any special issues or situations regarding Molybdenum-99 availability in any of the Agreement States?
Raise my awareness of medical issues in your state.
Provide information to me that you want to bring to ACMUI’s attention.
Provide to me any ideas/issues that I may suggest as topics for the April 2013 meeting.
Email me anytime [email protected]